Furthermore, levels of circulating protein and mRNA encoding for interleukin- (IL)-1, IL-6 and tumor necrosis factor (TNF)-α are reduced by the administration of synthetic cannabinoids in preclinical models of multiple sclerosis and periodontitis (Abidi et al., 2018, Croxford and Miller, 2003). This evidence concerns the gene TNF and multiple sclerosis.